<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">SANP</journal-id>
      <journal-title-group>
        <journal-title>Swiss Archives of Neurology, Psychiatry and Psychotherapy</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2297-7007</issn>
      <issn pub-type="ppub">2297-6981</issn>
      <publisher>
        <publisher-name>EMH Schweizerischer Ärzteverlag AG</publisher-name>
        <publisher-loc>Farnsburgerstrasse 8
CH-4132 Muttenz</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">03197</article-id>
      <article-id pub-id-type="doi">10.4414/sanp.2020.03197</article-id>
      <article-categories>
        <!-- rubric -->
        <subj-group subj-group-type="Article Type">
          <subject>Review article</subject>
        </subj-group>
        <!-- topics -->
        <subj-group subj-group-type="Classification">
          <subject>Schizophrenia, schizotypal and delusional disorders</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Magnetic resonance imaging for early detection schizophrenia</article-title>
      </title-group>
      <contrib-group>
        <contrib id="author-1" contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Kirschner</surname>
            <given-names>Matthias</given-names>
          </name>
          <email>matthias.kirschner@puk.zh.ch</email>
          <aff>Zürich | 8032 | SWITZERLAND</aff>
        </contrib>
        <contrib id="author-2" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Kaiser</surname>
            <given-names>Stefan</given-names>
          </name>
          <email>stefan.kaiser@hcuge.ch</email>
          <aff>Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Chemin du Petit-Bel-Air, 1226 Thônex, Switzerland.</aff>
        </contrib>
        <contrib id="author-3" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Seifritz</surname>
            <given-names>Erich</given-names>
          </name>
          <email>erich.seifritz@bli.uzh.ch</email>
          <aff>Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital, University of Zurich, Lenggstrasse 31, 8032 Zurich, Switzerland</aff>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" date-type="pub" iso-8601-date="2021.06.17">
        <day>17</day>
        <month>06</month>
        <year>2021</year>
      </pub-date>
      <volume>171</volume>
      <issue>03</issue>
      <fpage>0</fpage>
      <lpage>0</lpage>
      <permissions>
        <copyright-statement>Copyright: EMH Schweizerischer Ärzteverlag AG</copyright-statement>
        <copyright-year>2020</copyright-year>
        <copyright-holder>EMH Schweizerischer Ärzteverlag AG</copyright-holder>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p>"Swiss Archives of Neurology, Psychiatry and Psychotherapy" is an open access publication of EMH published in accordance with the terms of the Creative Commons licence attribution - NonCommercial - NoDerivatives 4.0 International. You are free to share, copy and redistribute the material in any medium or format under the following terms:</license-p>
          <license-p>Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.</license-p>
          <license-p>NonCommercial — You may not use the material for commercial purposes.</license-p>
          <license-p>NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.</license-p>
          <license-p>"Non-commercial" means not primarily intended for or directed towards commercial advantage or monetary compensation. The incorporation of publications in commercial products, the use of publications to advertise for commercial products or services and any other usage that directly or indirectly pursues commercial interests is subject to the express previous consent of the publishing house as part of a written agreement.</license-p>
          <license-p>Please send us your request in writing. Exact indication of the publication from which you would like to reproduce material and detailed information about its intended use help to facilitate and expedite request processing.</license-p>
        </license>
      </permissions>
      <abstract abstract-type="article" xml:lang="en">
        <p>Schizophrenia is a complex and severe mental disorder and is characterized by a heterogenous set of different symptoms. Although the current diagnosis of schizophrenia is still based on clinical assessments and operationalized symptom criteria, magnetic resonance imaging (MRI) assessments are important for the differential diagnosis of brain pathologies and potential organic causes of psychosis. In schizophrenia research, MRI and other neuroimaging techniques are already indispensable and of utmost relevance to better understand disrupted brain networks and neurotransmitter systems as well as neuroanatomical signatures related to schizophrenia. This article aims to bridge the gap between the current clinical utility of MRI and recent advances from MRI research in identifying neural substrates related to the development and treatment of schizophrenia. We first describe the current evidence and recommendations for the clinical utility of structural MRI in the diagnostic workup of patients with psychotic symptoms. The second part of this article provides a brief overview of how recent functional MRI (fMRI) research extends our knowledge of dopamine and reward system dysfunction in schizophrenia over the last years. Collectively, these studies provide growing evidence that basic principles of information processing such as salience evaluation and context-dependent efficient neural adaptation are a) disrupted across different stages of the schizophrenia spectrum and b) may be fundamental underlying neural mechanisms in the development of psychosis. While these findings are an important contribution to understand neural basis of schizophrenia, they cannot yet be translated into individualized treatment. Future work should therefore capitalize on the manifold potential of multimodal MRI and further the development of MRI applications for diagnostics and individualized treatment in schizophrenia.</p>
      </abstract>
    </article-meta>
  </front>
  <body/>
  <back/>
</article>
